Arati Rao
@dukeleuk
Followers
175
Following
213
Media
11
Statuses
131
Executive Director Clinical Research, Kite-Gilead. Former Associate Professor of Medicine-Duke Cell Therapy. Tweets are personal
Palo Alto, CA
Joined April 2014
Season 13 of 2020 needs to be discontinued after 6 episodes. Enough is enough!
0
0
1
Thank you!
This is great news for patients with R/R MCL!! Congrats to @dukeleuk and her team. Thankful for your hard work and to have you as a mentor!
0
0
0
Led at Hackensack by the amazing @AndreGoyMD đđź
Great News: The FDA has approved the CAR T-cell therapy brexucabtagene autoleucel (Tecartus; formerly KTE-X19) as a treatment for adult patients with relapsed/refractory mantle cell #lymphoma.
0
0
0
This is epic! A broad label, accelerated approval that will help the many patients with relapsed refractory MCL! What an honor to have led this program with the most amazing team!
Congratulations to all patients and their families affected by mantle cell lymphoma! This is a milestone progress! U.S. FDA Approves Kiteâs Tecartusâ˘, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma | Gilead Sciences
0
0
3
2 of 3 patients with BTKi failure MCL have a Complete remission with KTEX19. Thank you @michaelwangmd đđź and all the investigators.
âŚ@michaelwangmd⊠presents data of ZUMA-2. 2 out of 3 patients with BTK-resistant MCL achieved CR. #ASH19
0
0
0
Great results shown by @michaelwangmd of the phase 2 ZUMA-2 trial for patients with R/R Mantle Cell Lymphoma treated with KTE-X19 CD19 CAR-T cell. Heavily pre treated population, specially after BTKi. Great overall response rate and durable responses. #ASH19
0
1
8
Thank you @AndreGoyMD for your support with the Z2 study.
ZUMA2 data on CART cells in R/R MCL suggests a new paradigm for B-cell Lymphoma. Greater than 90% response, 67% CR. Highly durable. Grateful to be part of this team and have a new option for our patients @JTCancerCenter @hackensackUMC.org #ASH19 @ASH_hematology
0
0
0
Grateful for the patients who enrolled in the Zuma2 study and for the physicians and research nurses who helped let this study enrolled.
Wang Zuma-2 KTE-X19 MCL ⢠high risk, enrichment for high Ki67, blastoid / pleomorphic ⢠all prior BTKi with most refractory to this line ⢠ORR 93% CRR 67% ⢠median PFS NR, 12.3mo median FU ⢠expected CRS and neurotox This is impressive data in v high risk gp #ASH19 #lymsm
0
0
4
Promising results presented by @michaelwangmd of the ZUMA-2 trial for patients with R/R Mantle Cell Lymphoma treated with KTE-X19 CD19 #CARTcell. In a heavily pre-treated population â
ORR 93% â
CR 67% â
With a median FU of 27 months, 43% of patients remained in remission. #ASH19
0
8
20
A great day for MCL pts. @michaelwangmd of @MDAndersonNews presented Ph II ZUMA-2 data for KTE-X19 CAR T-cell. 60 evaluable pts, median f/u 12.3 months, ORR 93%, CR in 67%. 1 yr PFS 61%, 1 yr OS 83%. Median survival times not reached. Well tolerated with no grade 5 CRS or ICANS.
0
6
12
Proud to be part of the #KITE team that developed KTEX19 for RR MCL.
CONGRESS | #ASH19 | @michaelwangmd from @MDAndersonNews presents promising interim efficacy and safety results from ZUMA-2 trial evaluating KTE-X19, an anti-CD19 CAR T cell therapy in patients with R/R MCL. ORR 93%, CR 67% with manageable toxicity #lymsm
0
0
2
Phase 2 ZUMA-2 Anti-CD19 CAR T Cell Therapy in R/R MCL @michaelwangmd updated results: 75% cure rate durable at two years!! #ASH19 @ASH_hematology @hackensackUMC.org
0
1
4
Thanks @tobyeyre82 We hope it will be practice changing in the UK too. The full data set will speak volumes!
Interesting data. Congrats to authors. Suspect will be practice changing in US. Difficult to find MCL pts with 4 prior lines+ECOG 0. (53% in ZUMA2). Speaks to pt selectivity going into these studies. What this means for broader pop of post BTKi MCL pts harder to predict #ASH19
0
0
0
Excited to present ZUMA2 data of KTE-X19 in R/R MCL at #ASH19 which has also been selected for âBest Of ASHâ -that too with preliminary data of 28 patients. Eager to share the full data set with the oncology community at the oral presentation! https://t.co/XRRDxqshDs
0
2
5
Gone too soon but did more on earth than most people do in a lifetime. The legacy of Arti Hurria must live on.
Hi ASCO Women Who Conquer Cancer, we do need to make this happen so Artiâs generous mentorship is remembered forever. Please nominate her!!!!
1
1
2
FLT3 AML drugs dominating #ASH15 Midostaurin. Sorafenib. Crenolanib and now Gilteritinib #toungetwister
1
2
5